Purple Biotech (PPBT) Return on Capital Employed (2015 - 2026)

Purple Biotech (PPBT) has 12 years of Return on Capital Employed data on file, last reported at 248.21% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 22433.0% year-over-year to 248.21% in Q1 2026; TTM through Mar 2026 was 248.21%, a 22433.0% increase from a year earlier, with the FY2025 full-year figure at 140.44%, up 11044.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 248.21%, up from 133.51% in the prior quarter.
• Over the last five years, Return on Capital Employed for PPBT reached as high as 248.21% in Q1 2026 and fell as low as 16.39% in Q3 2025.
• Historically, Return on Capital Employed has averaged 60.47% across 5 years, with a median of 45.64% in 2022.
• Across the five-year window, Return on Capital Employed plunged 4565 bps in 2025 and soared 22433 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 45.64% in 2022, then surged by 39 bps to 63.48% in 2023, then slumped by 46 bps to 34.51% in 2024, then jumped by 287 bps to 133.51% in 2025, then soared by 86 bps to 248.21% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 248.21% in Q1 2026, 133.51% in Q4 2025, and 16.39% in Q3 2025.